4D Molecular Therapeutics, Inc. (FDMT) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated March 28, 2022, serves as a current report for 4D Molecular Therapeutics, Inc. (4DMT). The filing announces the company's audited financial results for the fiscal year ended December 31, 2021. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of the full-year 2021 audited results.
Guidance, Outlook, and Risks
The filing references a press release titled "4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2021 and Provides Operational Highlights." However, the text of this 8-K does not include specific guidance, management commentary, risk factors, contingencies, or unusual items. Investors must refer to Exhibit 99.1 for these details.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific 2021 revenue, net loss, and cash position figures.
- Verify operational highlights and pipeline updates mentioned in the referenced press release.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check for any forward-looking statements or guidance provided in the full press release text.